Eric Hansen has taken the reins as CEO of Austin, Texas-based Pantheon Spinal after the company’s merger with Summit Spine.
Former Osseus CEO, Eric Hansen, to Lead Pantheon Spinal
1 min read Premium comments
Secondary#pantheonspinal#erichansen
Hansen, co-founder and former CEO of Osseus Fusion Systems, will be bringing his business acumen, funding, and some technology along with him. The Pantheon Spinal model continues to be “built by surgeons for surgeons” and the company’s goals include cutting hospital expenses and lowering costs by eliminating unnecessary instrumentation and reducing the number of implants to shrink tray size and weight.
Dr. Scott Spann founded Pantheon Spinal after his invention of the Epiphany lateral lumbar interbody fusion device for L5-S1 fusion. The implant, cleared by the FDA in 2013, is designed to be inserted through an oblique approach system that Spann has dubbed A.T.L.A.S. for anterior-to-lateral approach system. Spann holds the patents for the approach, the device, as well as associated instrumentation.
Pantheon Spinal also manufactures the Pontus interbody fusion device for up to 2-level fusion from L2-S1 via a lateral or anterior approach. Spann will remain as the company’s chief medical advisor for the Epiphany implant. With additional funding and leadership, the reinvigorated venture is expected to generate million-dollar revenue immediately.
The FDA cleared the Summit Spine Channel and Yellowstone interbody fusion systems in a wide range of sizes in 2017.
Hansen, excited about his new role, said, “I look forward to the challenge of another start up.…I plan on executing to the same results: building a unique brand with a team that has vast industry experience. We stand united in faith and power during this worldly chaos.…We will be ready for those who are on the front line now when our opportunity is granted!” In addition to his experience, Hansen will be bringing the Blue Topaz/CompresSIve sacroiliac screw designed for sacroiliac joint fusion.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.